Evaluation of three commercial methods of susceptibility testing for ceftolozane/tazobactam against carbapenem-resistant Pseudomonas aeruginosa
Enfermedades infecciosas y microbiologia clinica (English ed.) · 2023
DOI: 10.1016/j.eimce.2022.09.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Enfermedades infecciosas y microbiologia clinica (English ed.), 2023. Verfasst von Lorena López-Cerero und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Gestión Clínica de Microbiología y Enfermedades infecciosas, Hospital Virgen Macarena, Sevilla, Spain; Departamento de Microbiología, Facul…. Hauptthemen laut MEDLINE: Pseudomonas Infections, Cross Infection. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, European Regional Development Fund.
Abstract (Originalsprache)
INTRODUCTION: Ceftolozane/tazobactam has shown excellent activity against Pseudomonas aeruginosa, but this drug is not always included in commercial panels. The aim of the study was to evaluate the performance of 2 gradient strips (BioMérieux and Liofilchem) and a commercial microdilution panel (Sensititre, EURGNCOL panel) using this combination against carbapenem-resistant P. aeruginosa isolates. METHODS: Three commercial methods were tested with 41 metallo-beta-lactamase-producing and 59 non-carbapenemase-producing P. aeruginosa isolates. Broth microdilution was used as reference. RESULTS: All carbapenemase-producing isolates and only one non-producing isolate were resistant to this antibiotic. Both essential agreement and bias were outside the acceptance intervals since MIC values were higher than reference values for all three methods. The Kappa index indicated poor or weak agreement. Changes in clinical categories were observed in 3 isolates. CONCLUSIONS: The three methods yielded poor agreement with the reference. Despite the differences in MIC values, fewer than 3% involved category changes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unidad de Gestión Clínica de Microbiología y Enfermedades infecciosas, Hospital Virgen Macarena, Sevilla, Spain; Departamento de Microbiología, Facultad de Medicina de Sevilla, Sevilla, Spain; Instituto de Biomedicina d…
- Departamento de Microbiología, Facultad de Medicina de Sevilla, Sevilla, Spain; Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen Macarena/CSIC/Universidad de Sevilla, Spain.
- Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Spain.
- Servicio de Microbiología, Complejo Hospitalario Torrecárdenas, Almería, Spain.
- Servicio de Microbiología, Hospital Regional Universitario, Málaga, Spain.
Förderung
- Instituto de Salud Carlos III
- European Regional Development Fund
Zitieren
APA
López-Cerero, L., Ballesta, S., López, C. E., Sánchez-Yebra, W., Rojo-Martin, M. D., & Pascual, A. (2023). Evaluation of three commercial methods of susceptibility testing for ceftolozane/tazobactam against carbapenem-resistant Pseudomonas aeruginosa. Enfermedades infecciosas y microbiologia clinica (English ed.). https://doi.org/10.1016/j.eimce.2022.09.014
Vancouver
López-Cerero L, Ballesta S, López CE, Sánchez-Yebra W, Rojo-Martin MD, Pascual A. Evaluation of three commercial methods of susceptibility testing for ceftolozane/tazobactam against carbapenem-resistant Pseudomonas aeruginosa. Enfermedades infecciosas y microbiologia clinica (English ed.). 2023. doi:10.1016/j.eimce.2022.09.014
BibTeX
@article{LpezCerero2023,
author = {López-Cerero, Lorena and Ballesta, Sofia and López, Cristina Elías and Sánchez-Yebra, Waldo and Rojo-Martin, María Dolores and Pascual, Alvaro},
title = {Evaluation of three commercial methods of susceptibility testing for ceftolozane/tazobactam against carbapenem-resistant Pseudomonas aeruginosa},
journal = {Enfermedades infecciosas y microbiologia clinica (English ed.)},
year = {2023},
doi = {10.1016/j.eimce.2022.09.014}
}
EUVIMED